<DOC>
	<DOCNO>NCT00893217</DOCNO>
	<brief_summary>The purpose study valuate safety tolerability Betaseron .</brief_summary>
	<brief_title>BEYOND Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Diagnosis RRMS define follow McDonald diagnostic criterion ( McDonald et al 2001 ; see Appendix 16.1.1 [ ( Protocol Appendix 5 ] ) : Two relapse objective clinical evidence ( history present ) least 2 lesion Two relapse objective clinical evidence ( history present ) 1 lesion ; dissemination space , demonstrate MRI ( Barkhof/Tintoré criterion ) 2 MRI T2 lesion consistent MS plus positive CSF . One relapse objective clinical evidence ( history present ) least 2 lesion , dissemination time , demonstrate sign disease activity ( new Gd+ lesion new T2 lesion ) MRI scan least 3 month onset clinical event . One relapse objective clinical evidence ( history present ) 1 lesion , dissemination space , demonstrate MRI ( Barkhof/Tintoré criterion ) ; 2 MRI T2 lesion consistent MS plus positive CSF , dissemination time , demonstrate sign disease activity ( new Gd+ lesion new T2 lesion ) MRI scan least 3 month onset clinical event . 18 55 year age Score 05.5 Kurtzke Expanded Disability Status Scale ' ( EDSS ; see Appendix 16.1.1 [ Protocol Appendix 4 ] ) Naïve immunomodulating therapy previously treat immunomodulating therapy interferon ( IFN ) 30 day prior start study If female childbearing potential , agreement practice adequate contraception method ( IUCD , condom , oral contraceptive , adequate barrier contraception ) Negative serum pregnancy test result . Signed dated statement inform consent Clinically significant heart disease uncontrolled cardiac dysrhythmia , angina pectoris , cardiomyopathy , congestive heart failure History severe depression , suicide attempt , current suicidal ideation Clinically significant liver , renal , bone marrow dysfunction define follow laboratory evaluation : bone marrow dysfunction : Hb &lt; 8.5 g/dl WBC &lt; 2.5 x 109/L platelet count &lt; 125 x 109/L renal dysfunction : creatinine &gt; 1.8 mg/dL liver dysfunction : ASAT ( SGOT ) &gt; 3xupper limit normal bilirubin &gt; 2x upper limit normal Epilepsy adequately control treatment Any condition could interfere MRI evaluation study Known allergy human proteins include albumin IFN , mannitol gadolinium Participation clinical study within past 30 day use/intake investigational drug within last 3 month prior study entry Prior treatment monoclonal antibody therapy , cladribine total lymphoid irradiation Treatment cytotoxic immunosuppressive therapy ( except systemic steroid adrenocorticotropic hormone [ ACTH ] ) within 6 month prior study entry ; systemic steroid ACTH within 1 month prior study entry Presence monoclonal gammopathy Inability tolerate NSAIDs acetaminophen Pregnancy lactation History alcohol drug abuse Inability administer subcutaneous injection either self caregiver Medical , psychiatric condition compromise patient 's ability give inform consent , understand patient information , comply study protocol , complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>